Although the majority of patients with chronic myeloid leukemia do well with treatment with tyrosine kinase inhibitors (TKIs), some patients still have inferior outcomes. There are many factors that might play a part, including the different BCR-ABL1 transcript types at baseline. The current study was performed to determine the possible impact of different transcripts on the treatment responses and outcomes of patients with chronic myeloid leukemia who are receiving TKI therapy. The authors performed a systematic literature search by using the terms b2a2/b3a2, e13a2/e14a2, or transcript type. e14a2 was the more common transcript type. The majority of the studies demonstrated no significant difference regarding age, sex, leukocyte counts, an...
There are different BCR-ABL1 fusion genes that are translated into proteins that are different from ...
Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::AB...
Chronic myeloid leukemia patients with different BCR-ABL transcripts might respond differently to Im...
The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. I...
The most frequent BCR-ABL1 fusion transcripts in chronic myeloid leukemia (CML) are the e13a2 (b2a2)...
Background. The fusion protein encoded by the BCR-ABL1 fusion gene may differ in size, but the great...
Introduction and objective: In this study, we evaluated the influence of the transcript type on hema...
The vast majority of chronic myeloid leukemia patients express a BCR-ABL1 fusion gene mRNA encoding ...
Purpose: The genomic break on the major breakpoint cluster region of chromosome 22 results in two BC...
Background: The clinical significance of BCR-ABL transcript type in the tyrosine kinase inhibitors (...
Chronic myeloid leukemia (CML) is characterized by the BCR-ABL fusion gene. Different types of BCR-...
Early reduction of BCR-ABL1 transcript levels has been associated with improved outcome in chronic m...
There are different BCR-ABL1 fusion genes that are translated into proteins that are different from ...
Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::AB...
Chronic myeloid leukemia patients with different BCR-ABL transcripts might respond differently to Im...
The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. I...
The most frequent BCR-ABL1 fusion transcripts in chronic myeloid leukemia (CML) are the e13a2 (b2a2)...
Background. The fusion protein encoded by the BCR-ABL1 fusion gene may differ in size, but the great...
Introduction and objective: In this study, we evaluated the influence of the transcript type on hema...
The vast majority of chronic myeloid leukemia patients express a BCR-ABL1 fusion gene mRNA encoding ...
Purpose: The genomic break on the major breakpoint cluster region of chromosome 22 results in two BC...
Background: The clinical significance of BCR-ABL transcript type in the tyrosine kinase inhibitors (...
Chronic myeloid leukemia (CML) is characterized by the BCR-ABL fusion gene. Different types of BCR-...
Early reduction of BCR-ABL1 transcript levels has been associated with improved outcome in chronic m...
There are different BCR-ABL1 fusion genes that are translated into proteins that are different from ...
Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::AB...
Chronic myeloid leukemia patients with different BCR-ABL transcripts might respond differently to Im...